Working… Menu

Study of XL999 in Patients With Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00277303
Recruitment Status : Terminated (Study was terminated due to cardiac toxicities in the subjects)
First Posted : January 16, 2006
Last Update Posted : February 22, 2010
Information provided by:
Symphony Evolution, Inc.

Brief Summary:
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic colorectal cancer (CRC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: XL999 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Colorectal Cancer
Study Start Date : December 2005
Actual Primary Completion Date : August 2006
Actual Study Completion Date : February 2007

Intervention Details:
  • Drug: XL999
    XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.

Primary Outcome Measures :
  1. Response rate [ Time Frame: Inclusion until disease progression ]
  2. Safety and tolerability [ Time Frame: Inclusion until 30 days post last treatment ]

Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: Inclusion until disease progression ]
  2. Duration of response [ Time Frame: Inclusion until disease progression ]
  3. Overall survival [ Time Frame: Inclusion until last Follow-up post last treatment or death ]
  4. Pharmacokinetic (PK) and Pharmacodynamic (PD) parameters [ Time Frame: Samples will be collected pre-dose and immediately at the end for subjects in the second stage of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and females with histologically confirmed metastatic colorectal cancer
  • Measurable disease according to Response Criteria for Solid Tumors (RECIST)
  • At least 1 prior therapeutic regimen (chemotherapy or biologic)
  • ECOG performance status of 0 or 1
  • Life expectancy ≥3 months
  • Adequate organ and marrow function
  • No other malignancies within 5 years
  • Signed informed consent

Exclusion Criteria:

  • Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
  • Treatment with systemic anticancer therapy within 30 days of XL999 treatment
  • Subject has not recovered to ≤ grade 1 or to within 10% of baseline from adverse events due to other medications administered >30 days prior to study enrollment
  • History of or known brain metastases, current spinal cord compression, or carcinomatous meningitis
  • Uncontrolled and/or intercurrent illness
  • Pregnant or breastfeeding females
  • Known HIV

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00277303

Layout table for location information
United States, California
California Cancer Care, Inc.
Greenbrae, California, United States, 94904
United States, Florida
Integrated Community Oncology Network; Division of Clinical Research
Jacksonville, Florida, United States, 32256
Hematology Oncology Associated of the Treasure Coast
Port St. Lucie, Florida, United States, 34952
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Joliet Oncology-Hematology Associated, Ltd.
Joliet, Illinois, United States, 60435
United States, Indiana
Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202
United States, New York
Hematology Oncology Associates of Rockland, PC
New City, New York, United States, 10956
United States, Texas
Center for Oncology Research and Treatment, PA
Dallas, Texas, United States, 75230
Sponsors and Collaborators
Symphony Evolution, Inc.
Layout table for investigator information
Study Director: Lynne Bui, MD Exelixis
Layout table for additonal information
Responsible Party: Charles W. Finn, PhD, President and CEO, Symphony Evolution, Inc. Identifier: NCT00277303    
Other Study ID Numbers: XL999-206
First Posted: January 16, 2006    Key Record Dates
Last Update Posted: February 22, 2010
Last Verified: February 2010
Keywords provided by Symphony Evolution, Inc.:
Colon Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases